“We continue to make meaningful progress across our pneumococcal conjugate vaccine (PCV ... a safety profile similar to Prevnar 20® (PCV20) across all doses studied. All VAX-24 doses ...

May 07, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine ... Company's 24-valent PCV candidate, in healthy infants. In this study, VAX-24 was well-tolerated and ...

Calabrese also said that the 15-valent (PCV15), 20-valent (PCV20), and 21-valent (PCV21) pneumococcal conjugate vaccines are indicated for all PCV-naïve adults aged 50 years and older and for ...

The introduction of malaria vaccines in nearly 20 African countries marks an important milestone in the fight against malaria. Global coverage of pneumococcal conjugate vaccines, which protect ...

Measles cases reached an estimated 10.3 million in 2023, a 20% increase compared to ... increases in global coverage of pneumococcal conjugate vaccines, particularly in the South-East Asia Region ...

The blue-chip Dow Jones Industrial Average increased by 0.7% READ ALSO: 11 Best Stocks Under $15 to Buy According ... promising VAX-31 pneumococcal conjugate vaccine (PCV) data in adults last ...

The World Health Organisation (WHO), UNICEF and Gavi have warned that the rising cases of vaccine-preventable diseases are threatening progress made over the years through immunisation. In a joint ...

pneumoniae strains in adults ... strongly as the newer conjugate vaccines. In a statement, the drugmaker said it would be "the first pneumococcal conjugate vaccine specifically designed for ...

Measles cases reached an estimated 10.3 million in 2023, representing a 20% increase from 2022 ... increases in global coverage of pneumococcal conjugate vaccines, particularly in the South ...